

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0107-100 101340 1PUS	

U.S.PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5633246		1997-05-27	McKittrick et al.	
	2	5744467		1998-04-28	McKittrick et al.	
	3	5306817		1994-04-26	Thiruvengadam et al.	
	4	RE37721		2002-05-28	Rosenblum et al.	
	5	5846966		1998-12-08	Rosenblum et al.	
	6	5767115		1998-06-16	Rosenblum et al.	
	7	5631365		1997-05-20	Rosenblum et al.	
	8	5739321		1998-04-14	Wu et al.	

/Mark Berch/ (09/11/2009)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0107-100 101340 1PUS	

	9	5756470		1998-05-26	Yumibe et al.	
	10	5886171		1999-03-23	Wu et al.	
	11	5919672		1999-07-06	Homann et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**FOREIGN PATENT DOCUMENTS**

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0250060	WO		2002-06-27	Avantis Pharma Deutschland GMBH		<input type="checkbox"/>
	2	2004005247	WO		2004-01-15	AstraZeneca UK Limited		<input type="checkbox"/>
	3	9302048	WO		1993-02-04	Schering Corporation		<input type="checkbox"/>

/Mark Berch/ (09/11/2009)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0107-100 101340 1PUS	

	4	524595	EP		1993-01-27	Schering Corporation		<input type="checkbox"/>
	5	9414433	WO		1994-07-07	Schering Corporation		<input type="checkbox"/>
	6	9417038	WO		1994-08-04	Schering Corporation		<input type="checkbox"/>
	7	9501961	WO		1995-01-19	Schering Corporation		<input type="checkbox"/>
	8	9508532	WO		1995-03-30	Schering Corporation		<input type="checkbox"/>
	9	9526334	WO		1995-10-05	Schering Corporation		<input type="checkbox"/>
	10	9535277	WO		1995-12-28	Schering Corporation		<input type="checkbox"/>
	11	9609827	WO		1996-04-04	Pfizer Inc.		<input type="checkbox"/>
	12	9616037	WO		1996-05-30	Schering Corporation		<input type="checkbox"/>
	13	9619450	WO		1996-06-27	Schering Corporation		<input type="checkbox"/>
	14	9716455 /Mark Berch/ (09/11/2009)	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0107-100 101340 1PUS	

	15	9716424	WO		1997-05-09	Schering Corporation		<input type="checkbox"/>
	16	9745406	WO		1997-12-04	Schering Corporation		<input type="checkbox"/>
	17	0020623	WO		2000-04-13	Schering Corporation		<input type="checkbox"/>
	18	0034240	WO		2000-06-15	Schering Corporation		<input type="checkbox"/>
	19	0038725	WO		2000-07-06	G.D. Searle & Co.		<input type="checkbox"/>
	20	0060107	WO		2000-10-12	Schering Corporation		<input type="checkbox"/>
	21	0063703	WO		2000-10-26	Schering Corporation		<input type="checkbox"/>
	22	0218432	WO		2002-07-03	Aventis Pharma Deutschland		<input type="checkbox"/>
	23	0250027	WO		2002-06-27	Aventis Pharma Deutschland		<input type="checkbox"/>
	24	0250068	WO		2002-06-27	Aventis Pharma Deutschland		<input type="checkbox"/>
	25	0250090 /Mark Berch/ (09/11/2009)	WO		2002-06-27	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number	ASZN0107-100 101340 1PUS	

	26	02058685	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	27	02058696	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	28	02058731	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	29	02058732	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	30	02058733	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	31	02058734	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
	32	02066464	WO		2002-08-29	Kotobuki Pharmaceutical Co.		<input type="checkbox"/>
	33	02072104	WO		2002-09-19	Merck & Co., Inc.		<input type="checkbox"/>
	34	02079174	WO		2002-10-10	Schering Corporation		<input type="checkbox"/>
	35	02096415	WO		2002-12-05	Schering Corporation		<input type="checkbox"/>
	36	03026644 /Mark Berch/ (09/11/2009)	WO		2003-04-03	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10596731
Filing Date		
First Named Inventor	Susanne Alenfalk	
Art Unit		
Examiner Name		
Attorney Docket Number		ASZN0107-100 101340 1PUS

37	03088962	WO		2003-10-30	Merck & Co., Inc.		<input type="checkbox"/>
38	2004000803	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
39	2004000804	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
40	2004000805	WO		2003-12-31	Aventis Pharma Deutschland		<input type="checkbox"/>
41	2004010993	WO		2004-02-05	Merck Sharp & Dohme Limited		<input type="checkbox"/>
42	2004010948	WO		2004-02-05	Karykion Inc.		<input type="checkbox"/>
43	2004014947	WO		2004-02-19	Aventis Pharma Deutschland		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	McKittrick et al., "Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity," J Med Chem (1998) 41(5):752-759.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

/Mark Berch/ (09/11/2009)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596731
Filing Date	
First Named Inventor	Susanne Alenfalk
Art Unit	
Examiner Name	
Attorney Docket Number	ASZN0107-100 101340 1PUS

**EXAMINER SIGNATURE**

Examiner Signature	/Mark Berch/ (09/11/2009)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596731
Filing Date	
First Named Inventor	Susanne Alenfalk
Art Unit	
Examiner Name	
Attorney Docket Number	ASZN0107-100 101340 1PUS

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul K. Legaard/	Date (YYYY-MM-DD)	2006-11-16
Name/Print	Paul K. Legaard	Registration Number	38,534

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

/Mark Berch/ (09/11/2009)



## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

/Mark Berch/ (09/11/2009)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/